NGS may be useful in identifying MPN not detected by conventional methods (e.g., JAK2-exon 12 mutations in triple-negative MPN-SVT [60,61]) and in prognostication, but ultimately, it is yet to be determined if the information gained from NGS significantly impacts management. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.